X

Trial Profile

An Exploratory Study to Evaluate the Safety and Efficacy of AIV001 Intradermally Administered in Subjects With Biopsy-confirmed Basal Cell Carcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AIV 001 (Primary) ; AIV 001 (Primary)
Indications Basal cell cancer; Carcinoma
Focus Adverse reactions
Sponsors AiViva BioPharma

Most Recent Events

11 Dec 2023 Status changed from active, no longer recruiting to completed, according to a AiViva Biopharma media release.
11 Apr 2023 Planned End Date changed from 10 Mar 2023 to 23 Jun 2023.
11 Apr 2023 Planned primary completion date changed from 10 Dec 2022 to 23 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com